Reading this on a mobile device? Try our optimized mobile version here:

December 4, 2012Faster News for FasterCures

  Top News 
  • Myelin Repair Foundation looks to take charge of MS drug development
    Entrepreneur Scott Johnson is positioning his Myelin Repair Foundation as the leader in finding drugs that could reverse multiple sclerosis by repairing the protective lining of nerve cells in the spinal cord and brain. "The challenge in medical research is that there ultimately is no one in charge," said FasterCures Executive Director Margaret Anderson. The MRF is coordinating research at nine labs and has set up its own research lab in pursuit of results that big drugmakers can easily take to market. Bloomberg Businessweek (11/29) LinkedInFacebookTwitterEmail this Story
  News from FasterCures 
  • 4th annual Partnering for Cures meeting sparks great discussion, ideas for improving medical research
    Last week's Partnering for Cures conference in New York City brought together over 875 of the most forward-thinking innovators from across the medical research ecosystem. Through dozens of panels and presentations focused on everything from novel collaboration models to innovative funding mechanisms to creative clinical trial design, participants explored solutions for improving and speeding research progress, and getting new therapies to patients faster. Don't miss our special recap of the meeting in the FasterCures SmartBrief Special Report on Partnering for Cures, which will be sent on Dec. 14. LinkedInFacebookTwitterEmail this Story
Learn more about FasterCures ->FasterCures Home  |  Milken Institute


  Science and Technology 
  • Obama administration says AIDS-free generation is achievable
    Secretary of State Hillary Rodham Clinton laid out a plan to achieve an AIDS-free generation during a State Department ceremony last Thursday to recognize World AIDS Day. The framework calls for targeting high-risk populations, providing earlier treatment of HIV infections and implementing faster expansion of proven tools. Yahoo/The Associated Press (11/29) LinkedInFacebookTwitterEmail this Story
  • Report: Drug firms' R&D efforts could still be improved
    Improving research and development efforts, spending on neglected illnesses, innovative partnership and knowledge exchange depict the attempts of the 20 biggest pharmaceutical companies to boost treatment access in developing countries, according to a report by the Access to Medicine Foundation. The report indicated that there is room for improvement since the efforts are not spread evenly to develop treatments for all diseases. "Companies should support R&D capacity building initiatives, but public and philanthropic funders should step up to the plate and take the lead," said Javier Guzman, director of research at Policy Cures, a group working on neglected diseases. (11/30) LinkedInFacebookTwitterEmail this Story
  Finance and Economics 
  Policy and Regulation 
  • FDA creates collaborative partnership with medical device makers
    The FDA and medical device makers formed a nonprofit organization, the Medical Device Innovation Consortium, to work with one another and with patient advocacy groups, CMS, foundations and academia to speed device approvals while protecting patients. "I know there will be real advances and new approaches that will emerge from it," said FDA Commissioner Dr. Margaret Hamburg. Medtronic, Boston Scientific, Becton Dickinson, Abiomed and Cyberonics are among the medical device companies participating in the consortium. Reuters (12/3) LinkedInFacebookTwitterEmail this Story
  • Senate approves cancer research amendment added to defense bill
    The Senate approved the Recalcitrant Cancer Research Act, which instructs the NIH to create research frameworks for pancreatic and lung cancer. Sen. Tom Coburn, R-Okla., put a hold on the bill until last week because he objected to how the measure would serve to micromanage the NIH, saying, "We can serve patients best by allowing NIH to determine how to allocate its funding and manpower." The act was passed as an amendment to a defense bill that the White House has threatened to veto. The Hill/Healthwatch blog (11/29) LinkedInFacebookTwitterEmail this Story
  Society and Ethics 
  • Few new drugs for neglected diseases despite spending boost
    Product development investment for neglected diseases dropped by 1% between 2007 and 2011, while research and development spending on neglected diseases increased 28% over the same period, according to a survey commissioned by the Bill & Melinda Gates Foundation. Industry and philanthropists cut or shifted their budgets over the period to focus on a limited number of disease areas with the highest potential for commercialization. The report urges better coordination between governments, philanthropists and industry. PharmaTimes (U.K.) (12/3) LinkedInFacebookTwitterEmail this Story
  • FDA advisers discuss pediatric cancer meds
    A panel of FDA advisers is meeting to discuss testing four drugs with potential to treat childhood cancers. Relatively few children are affected by cancer, making robust clinical trial design difficult. The FDA requires drugmakers to study their products in children if children are prone to the target disease, and new legislation taking effect next month will require those studies even earlier. Bloomberg (12/4) LinkedInFacebookTwitterEmail this Story

FasterCures / The Center for Accelerating Medical Solutions is a nonprofit think tank and catalyst for action that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.

Subscriber Tools
Print friendly format | Web version | Search past news | Briefs by date | Privacy policy

Contact Us
FasterCures / The Center for Accelerating Medical Solutions
1101 New York Avenue, NW
Suite 620
Washington, DC 20005
(202) 336-8900 |
Media Inquiries
Cecilia Arradaza
Director of Communications

 Recent FasterCures SmartBrief issues:   Lead Editor:  Lisa Gough
Distributed by:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information